Case Study
|
By William B. Jones, Ph.D.,
Lonza
William B. Jones, senior vice president of pharmaceutical development at Corvus Pharmaceuticals, discusses his company’s selection of CDMO for its CPI-006 antibody program, which is currently under development as an oncology drug and investigation as a therapeutic for immune disorders and infectious diseases.
|